Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

sing was applied according to the study protocol. In both edoxaban treatment arms, the edoxaban dose was halved for patients with clinical factors that were known to increase the risk of bleeding (renal impairment, low body weight or concomitant use of certain P-glycoprotein inhibitors).1, 2 Patients receiving a reduced edoxaban dose in the 60 mg treatment arm had an annual incidence of stroke or SEE of 2.32% versus 2.68% for warfarin and a significantly reduced major bleeding incidence of 3.05% versus 4.85%. Patients receiving a reduced edoxaban dose in the 30 mg treatment arm had an annual incidence of stroke or SEE of 3.14% versus 2.68% for warfarin and a significantly reduced major bleeding incidence of 1.50% versus 4.85%.2

"The results from the ENGAGE AF-TIMI 48 trial showed that edoxaban may provide a new treatment option for the prevention of stroke or systemic embolic events that demonstrates comparable efficacy to warfarin, while significantly reducing the risk of major bleeding. In addition, we identified an appropriate dose regimen for patients with clinical factors such as renal impairment and low body weight," said Robert Giugliano, MD, SM, FAHA, FACC, Senior Investigator with the TIMI Study Group, Physician Cardiovascular Medicine, Brigham and Women's Hospital, Associate Professor of Medicine, Harvard Medical School, and Co-Global Lead Investigator of the ENGAGE AF-TIMI 48 trial. "In conducting this landmark trial we sought to provide clinicians with robust data, evident by the trial size and follow-up, high percentage of time in therapeutic range for the warfarin treatment arm, and very low rate of missing data. In addition, we specifically designed a comprehensive transition plan to protect patients from the undue risk of stroke and bleeding when switching to open-label anticoagulation at the end of the trial."

"The edoxaban clinical trial program, the largest in the history of Daiichi
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  TWi Pharmaceuticals, Inc. today ... United States Food and Drug Administration (FDA) on its ... USP, 23 mg, the generic equivalent to Eisai Inc.,s ... disease patients. TWi Pharmaceuticals is preparing to ... owned subsidiary, TWi Pharmaceuticals USA , ...
(Date:10/30/2014)... Electrodes are devices that convert ionic ... to diagnose as well as treat several ailments ... facilitate the detection of chemical reactions derived from ... of the patients. In addition, few electrodes such ... to perform minimally invasive surgical procedures. The electrodes ...
(Date:10/30/2014)... , Oct. 29, 2014 Hospital stretchers ... one location to another, inside or outside of ... hospital stretchers are also used for several specialized ... diagnostic and emergency platforms. The hospital ... well as future market potential of hospital stretchers ...
Breaking Medicine Technology:Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4Hospital Stretchers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Hospital Stretchers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... Recovery after Procedure Utilizing IlluminOss(TM) Photodynamic Bone Stabilization ... announced that one of the leading surgeons in ... first case in the world utilizing the innovative ... The IlluminOss Photodynamic Bone Stabilization System was ...
... is pleased to announce the fielding of a new syndicated report, ... Takeda Pharmaceutical Company Limited announced that they received FDA approval for ... 2009. Uloric (R) is indicated for the ... product for gout that has been approved in over forty years. ...
Cached Medicine Technology:IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile 2IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile 3
(Date:10/30/2014)... New Haven, CT (PRWEB) October 30, 2014 ... product categories are raising questions about the impact of ... as the marketing method most likely to influence a ... online research poll of 525 consumers conducted by radio ... in four product categories, isolating the results of respondents ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, 2014 (HealthDay ... three West African nations ravaged by the disease -- may ... Bruce Aylward, WHO,s assistant director general, said there,s been a ... increase in laboratory-confirmed cases. He said he was cautiously optimistic ... making some progress, The New York Times reported. ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Horse ... therapeutic horseback riding to special needs individuals in the ... on Saturday, November 15 from 10-2:00 p.m. at Bailey's ... is open to the public and is designed to ... , Admission to the HSS Round-Up is free. Ticket ...
(Date:10/30/2014)... 2014 REV'D Provision Co. announced today ... through a unique service called, The Feed . ... the everyday athlete. The Feed has taken the nutritional ... a system to pass that information on to the ... now available on The Feed!” says REV’D® marketing manager ...
(Date:10/30/2014)... 2014 Victory Healthcare, a privately ... third quarter infection rates and patient satisfaction scores. ... of only two percent or less, and the ... 98 percent. , “We are delighted with our ... satisfaction scores,” said Robert Helms, chairman and CEO ...
Breaking Medicine News(10 mins):Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3
... defibrillators and pacemakers are now equipped with wireless ... patients from repeated doctor visits. But this convenience ... researchers from three leading universities has demonstrated that ... their devices reprogrammed without the patients authorization or ...
... Mass., March 12 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... $645,870 compared to $210,289 for 2006. Revenue from the ... year as compared to,$210,289 for the prior year. This ... the result of the number of installations of the,Company,s ...
... Osteoporosis now available FREE online , Summaries and critical ... , The International Osteoporosis Foundation has announced that its ... free online to help readers keep up with the ... in Osteporosis provides a timely update of the most ...
... at Financial Communications Forum, April 16, New York ... ... Forums, LLC today announced,six finalists for the 2008 Insight Award for Customer ... 2006, the,Award recognizes communications initiatives that provide information,customers of financial services need ...
... Mass., March 12 Swelling numbers of,infertile couples are ... and are in turn creating an acute shortage of ... (RSC) of New,England., As a result, RSC doctors ... other Asian ethnic groups in New England to consider ...
... . , A researcher from the Physical Anthropological ... developed the most complete database today to identify human ... 3D computerised techniques for facial reconstruction. This method will ... and it will avoid the need to perform an ...
Cached Medicine News:Health News:Implantable medical devices may expose patients to security, privacy risks; solutions suggested 2Health News:Implantable medical devices may expose patients to security, privacy risks; solutions suggested 3Health News:Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update 2Health News:Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update 3Health News:Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update 4Health News:Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update 5Health News:Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update 6Health News:Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update 7Health News:Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update 8Health News:New England Area Fertility Experts Issue Call for Ethnic Egg Donors 2Health News:Body identification by facial reconstruction will cost less time and money 2
... Pediatric Ankle Cryo/Cuff is specifically designed to ... Using a combination of controlled compression and ... pain. The Pediatric Ankle Cryo/Cuff is ideal ... episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff is ...
... Aircast VenaFlow System (a prophylaxis for DVT), ... styles: calf, foot, and thigh, to suit ... from light, cool, comfortable material to promote ... be placed directly against the skin. With ...
... A new cast boot specially ... on a double rocker sole for ... built around a narrow last so ... plaster cast boots, and with our ...
This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption....
Medicine Products: